FGF23 and Cardiac Remodeling in Chronic Kidney Disease: A Rapid Review and Exploratory Quantitative Synthesis

Left ventricular hypertrophy (LVH), elevated left ventricular mass index (LVMI), diastolic dysfunction, heart failure, and cardiovascular mortality are common in chronic kidney disease (CKD). Fibroblast growth factor 23 (FGF23) rises early in CKD and is linked to cardiac remodeling, but consistency across studies is unclear. We conducted a rapid review of FGF23 and cardiac outcomes in CKD, incorporating a reanalyzed unpublished single-center cohort, and pooled effect estimates where at least 2 studies reported comparable metrics. A structured web-based search (August 2026) identified 11 candidate studies on FGF23 and cardiac outcomes in CKD; 9 met eligibility, including 1 unpublished investigator-held cohort (n = 80) reanalyzed for this review. Pooling (inverse variance) was performed only where at least 2 studies reported comparable metrics; all pooled estimates are exploratory, below the prespecified 3-study minimum. For FGF23 and LVH, using a derived LVH variable from the present cohort, a pooled log-FGF23 odds ratio (OR) across 2 adult-CKD studies (n = 242) was 1.33 (95% confidence interval [CI] 0.92-1.93), I2 = 78%; a pediatric study (OR 2.53, n = 587) was consistent in direction but unpooled. For LVMI, correlations were not pooled; a Chronic Renal Insufficiency Cohort cohort showed higher LVMI only in the top quartile. For heart failure/cardiovascular mortality, a pooled hazard ratio across 2 studies (n = 374) was 2.37 (95% CI 1.47-3.84), I2 = 0%, with LVMI mediating only 7-22% in Chronic Renal Insufficiency Cohort. FGF23 was not significantly associated with diastolic dysfunction after adjustment (OR 1.51/standard deviation, 95% CI 0.92-2.47). The available evidence, though sparse and heterogeneous, is directionally consistent with a positive FGF23-cardiac remodeling association in CKD. Certainty is very low throughout; a full multi-database search is needed before a definitive conclusion.

Authors

Institutions

Publication Details

Journal
Cardiology in Review
Published
2026-11-19
DOI
https://doi.org/10.1097/crd.0000000000001553
Primary Topic
Parathyroid Disorders and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

FGF23 and Cardiac Remodeling in Chronic Kidney Disease: A Rapid Review and Exploratory Quantitative Synthesis

Ashutosh Rath, Jayanthi Rangarajan, Jaiju James Chakola, Manikantan Sekar et al.
Cardiology in Review
Parathyroid Disorders and Treatments
article

FGF23 and Cardiac Remodeling in Chronic Kidney Disease: A Rapid Review and Exploratory Quantitative Synthesis

Ashutosh Rath, Jayanthi Rangarajan, Jaiju James Chakola, Manikantan Sekar, Gnanasambandan Ramanathan, Karthick Rajendren, Sundar Raj Nithianantham
article en

Abstract

Left ventricular hypertrophy (LVH), elevated left ventricular mass index (LVMI), diastolic dysfunction, heart failure, and cardiovascular mortality are common in chronic kidney disease (CKD). Fibroblast growth factor 23 (FGF23) rises early in CKD and is linked to cardiac remodeling, but consistency across studies is unclear. We conducted a rapid review of FGF23 and cardiac outcomes in CKD, incorporating a reanalyzed unpublished single-center cohort, and pooled effect estimates where at least 2 studies reported comparable metrics. A structured web-based search (August 2026) identified 11 candidate studies on FGF23 and cardiac outcomes in CKD; 9 met eligibility, including 1 unpublished investigator-held cohort (n = 80) reanalyzed for this review. Pooling (inverse variance) was performed only where at least 2 studies reported comparable metrics; all pooled estimates are exploratory, below the prespecified 3-study minimum. For FGF23 and LVH, using a derived LVH variable from the present cohort, a pooled log-FGF23 odds ratio (OR) across 2 adult-CKD studies (n = 242) was 1.33 (95% confidence interval [CI] 0.92-1.93), I2 = 78%; a pediatric study (OR 2.53, n = 587) was consistent in direction but unpooled. For LVMI, correlations were not pooled; a Chronic Renal Insufficiency Cohort cohort showed higher LVMI only in the top quartile. For heart failure/cardiovascular mortality, a pooled hazard ratio across 2 studies (n = 374) was 2.37 (95% CI 1.47-3.84), I2 = 0%, with LVMI mediating only 7-22% in Chronic Renal Insufficiency Cohort. FGF23 was not significantly associated with diastolic dysfunction after adjustment (OR 1.51/standard deviation, 95% CI 0.92-2.47). The available evidence, though sparse and heterogeneous, is directionally consistent with a positive FGF23-cardiac remodeling association in CKD. Certainty is very low throughout; a full multi-database search is needed before a definitive conclusion.

Cardiology in Review
SRM Institute of Science and Technology (IN), Sri Ramachandra Institute of Higher Education and Research (IN), SRM Medical College Hospital and Research Centre (IN)
Parathyroid Disorders and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon